Rasonque (Daraxonrasib)

Daraxonrasib is a medicine used to treat pancreatic cancer that has spread. It is taken as a pill by mouth. It works by blocking RAS, a switch inside cells that is stuck in the 'on' position in most pancreatic cancers and makes them grow.

Brand names:Rasonque
Medication

What people taking Rasonque (Daraxonrasib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Rasonque (Daraxonrasib) for Pancreatic Cancer?

NameHow it went

About Rasonque (Daraxonrasib)

What It's For

Daraxonrasib, sold as Rasonque, is a daily cancer pill approved in the US in 2026 for adults with pancreatic adenocarcinoma, the most common type of pancreatic cancer, once it has spread to other parts of the body (metastatic disease). It is used after at least one earlier round of drug treatment, usually chemotherapy, or for people who cannot take a combination of chemotherapy drugs. It is a targeted therapy rather than chemotherapy: it is designed to block a growth signal that almost all pancreatic cancers depend on. In the main trial, people whose cancer had grown after one earlier chemotherapy regimen lived longer on daraxonrasib than on a second chemotherapy regimen. It does not cure metastatic pancreatic cancer, but it is a meaningful new option at a stage where choices have been limited.

How It Works

Cells use proteins called RAS as on-off switches for growth. When RAS is switched on, it passes a signal telling the cell to grow and divide, then normally switches itself off. In more than 9 out of 10 pancreatic cancers, a change (mutation) in the KRAS gene leaves this switch stuck in the on position, so the growth signal never stops. Daraxonrasib attaches to a helper protein inside the cell and, together, they clamp onto RAS while it is switched on. That blocks RAS from passing its signal along and pushes it back toward the off state. It works on the mutated forms of RAS as well as the normal ones, which is why the label does not require a specific mutation for treatment. With the signal cut off, cancer cells grow more slowly or die. Because healthy skin, mouth and gut cells also rely on RAS signals to renew themselves, the same action explains many of its side effects.

Dosage & Administration

Daraxonrasib is a tablet taken by mouth once a day, at about the same time each day, with or without food. The usual dose is 300 mg. Swallow the tablets whole; do not chew, crush or split them. Treatment continues for as long as it is working and the side effects are manageable. Skin care starts on the first day, not after a rash appears. The care team typically prescribes a steroid cream for the face and chest and a moisturizing cream, and may add an antibiotic pill such as doxycycline to reduce the chance of a bad rash. Limiting sun exposure and using broad-spectrum sunscreen of SPF 30 or higher, plus hats and covering clothing, is part of the plan. If a dose is missed by more than 4 hours, skip it and take the next one at the usual time. If you vomit after a dose, do not take another that day. The oncologist commonly lowers the dose or pauses treatment to manage side effects, and may also change the dose when certain other medicines are needed.

Side Effects

Skin, mouth and gut side effects are the ones most people deal with. A rash, often acne-like on the face and chest, affects most people, usually within the first two weeks; dry or cracked skin, itching and sore, swollen skin around the fingernails or toenails are also common. Mouth sores, diarrhea, nausea, vomiting, tiredness, belly pain, swelling in the legs or arms, poor appetite and minor bleeding such as nosebleeds are also frequent. Routine blood tests often show changes, such as low protein, calcium or sodium levels, raised liver enzymes or lower blood counts, which the care team checks and treats. These effects are usually manageable but can become severe, and treating them early keeps treatment on track. Contact the care team right away for a spreading or painful rash, mouth sores that make eating, talking or swallowing hard, or diarrhea that is new or worsening, especially six or more bowel movements a day beyond your usual number. Two uncommon complications can be life threatening. Daraxonrasib can cause a tear in the stomach or bowel (gastrointestinal perforation): call the care team right away for stomach pain that is severe or will not go away, vomiting blood, black or tarry stool, or fever with chills. It can also cause lung inflammation (pneumonitis): call right away for a new or worsening cough, shortness of breath or wheezing. Sudden severe belly pain or severe trouble breathing needs emergency care.

Interactions & Warnings

Daraxonrasib interacts with many medicines, in both directions. Some drugs slow the liver enzyme (CYP3A) or the cell pump (P-gp) that clear it, raising its level in the blood and making side effects more likely; others speed that clearance and can make it less effective. The oncologist may avoid the combination or change the daraxonrasib dose. Cyclosporine, an immune-suppressing drug used after organ transplants and for some autoimmune conditions, should be avoided because it binds the same helper protein daraxonrasib uses. Daraxonrasib can also raise levels of some other drugs, which may need to be taken at least 4 hours apart. Give the oncologist and pharmacist a full list of prescriptions, over-the-counter medicines, vitamins and herbal supplements before starting, and check before adding anything new. Daraxonrasib can harm a developing baby. People who could become pregnant have a pregnancy test before starting and should use effective birth control during treatment and for 1 week after the last dose; men with a partner who could become pregnant should do the same. Tell the care team right away about a pregnancy. Do not breastfeed during treatment or for 1 week after the last dose.

What to Expect

The first weeks are often the busiest. Rash and diarrhea tend to appear early, mouth sores a little later, and the care team usually checks in often at first to adjust skin care, mouthwashes and anti-diarrhea medicines. Most people in the trial needed at least one pause, and over a third had a dose reduction, yet very few stopped for good because of side effects. A lower dose is a routine tool, not a sign that treatment has failed. The oncologist tracks whether it is working with periodic scans and regular blood tests. In the trial, tumors shrank in about 3 in 10 people, and the cancer was held back for a median of about 7 months, compared with about 3.5 months on chemotherapy. Median survival was about 13 months versus about 7 months. These are averages from people who were fairly active and well despite their cancer; individual results vary widely. When the cancer grows again, the team discusses other treatments, clinical trials or a focus on comfort care.

Questions to Ask Your Doctor

  1. 1.Why is daraxonrasib a better fit for me than another chemotherapy regimen or a clinical trial?
  2. 2.What should my skin, mouth and diarrhea plan look like from the first day, and when should I call?
  3. 3.Do any of my current medicines or supplements interact with daraxonrasib, and who should I check with before starting a new one?
  4. 4.How will we judge whether it is working, and what are the next options if it stops working?
  5. 5.Should palliative care join my team now to help with symptoms alongside treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.